CD86 and myeloid sarcoma: The obtained results to a large degree mitigate aforementioned concern, because our study reproduced a key finding from previously published ex vivo analyses of primary CSF B cells (7, 8), such as significantly higher levels of the co-stimulatory molecule CD80 (but not CD86) in CSF BCL derived from MS patients in comparison to controls (22) and trend for lower production of IL-10 observed in peripheral blood B cells derived from MS patients in comparison to HV (34).